LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
70.00
-1.67 (-2.33%)
At close: May 15, 2026, 4:00 PM EDT
68.65
-1.35 (-1.93%)
After-hours: May 15, 2026, 4:53 PM EDT
LivaNova Employees
LivaNova had 3,300 employees as of December 31, 2025. The number of employees increased by 400 or 13.79% compared to the previous year.
Employees
3,300
Change (1Y)
400
Growth (1Y)
13.79%
Revenue / Employee
$434,381
Profits / Employee
$32,468
Market Cap
3.85B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,300 | 400 | 13.79% |
| Dec 31, 2024 | 2,900 | 0 | - |
| Dec 31, 2023 | 2,900 | 0 | - |
| Dec 31, 2022 | 2,900 | -100 | -3.33% |
| Dec 31, 2021 | 3,000 | -1,000 | -25.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bruker | 11,085 |
| Integer Holdings | 11,000 |
| Bio-Rad Laboratories | 7,450 |
| Bio-Rad Laboratories | 7,450 |
| Haemonetics | 3,023 |
| iRhythm Holdings | 2,400 |
| NovoCure | 1,605 |
| Glaukos | 1,094 |
LIVN News
- 8 days ago - LivaNova price target lowered to $76 from $78 at Baird - TheFly
- 8 days ago - LivaNova price target raised to $90 from $85 at Mizuho - TheFly
- 9 days ago - LivaNova price target raised to $76 from $73 at Barclays - TheFly
- 9 days ago - LivaNova reports Q1 adjusted EPS 98c, consensus 90c - TheFly
- 9 days ago - LivaNova raises FY26 adjusted EPS view to $4.20-$4.30 from $4.15-$4.25 - TheFly
- 10 days ago - LivaNova Earnings Call Transcript: Q1 2026 - Transcripts
- 10 days ago - LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance - Business Wire
- 25 days ago - Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea - Business Wire